CervoMed
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 8
- Market Cap
- $137.5M
- Introduction
CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.
Q32 Bio's Bempikibart Shows Mixed Results, BioAge's Azelaprag Faces Safety Concerns, Stocks React
Q32 Bio's bempikibart showed promise in Phase IIa trial for alopecia areata (AA), achieving a 16% mean reduction in SALT score at week 24 compared to placebo.
CervoMed's Neflamapimod Fails to Meet Endpoints in Phase 2b DLB Trial Due to Suboptimal Drug Exposure
CervoMed's RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies (DLB) did not meet its primary or secondary endpoints.
FDA Grants Orphan Drug Status to CervoMed's Neflamapimod for Frontotemporal Dementia
The FDA has granted orphan drug designation to CervoMed's neflamapimod for frontotemporal dementia, a rare neurodegenerative disease.
CervoMed and Cognition Therapeutics Advance DLB Therapies in Phase II Trials
CervoMed and Cognition Therapeutics are both advancing novel therapies for dementia with Lewy bodies (DLB) in Phase II clinical trials, addressing a significant unmet need.
CervoMed Wins Prix Galien USA 2024 for Advances in Dementia with Lewy Bodies Treatment
CervoMed received the Prix Galien USA 2024 Best Startup award for its work on developing a treatment for Dementia with Lewy bodies (DLB).
CervoMed's Neflamapimod Shows Promise in Dementia with Lewy Bodies (DLB) Treatment
CervoMed's neflamapimod demonstrated a significant reduction in plasma GFAP levels, a key biomarker of neurodegenerative activity in DLB patients, in a Phase 2a trial.
CervoMed's Neflamapimod Shows Promise in Dementia with Lewy Bodies by Targeting Neurodegenerative Activity
CervoMed's neflamapimod demonstrates potential in treating Dementia with Lewy Bodies (DLB) by reducing neurodegenerative activity in the basal forebrain cholinergic system.
CervoMed's Neflamapimod Shows Promise in Dementia with Lewy Bodies Treatment
CervoMed's neflamapimod demonstrated a significant reduction in plasma GFAP levels (p=0.015 vs placebo) in Phase 2a trials, suggesting reduced neurodegenerative activity in DLB.
CervoMed's Neflamapimod Shows Promise in Dementia with Lewy Bodies by Targeting Neurodegenerative Activity
CervoMed's neflamapimod demonstrated a significant reduction in plasma GFAP levels, a key biomarker of neurodegenerative activity in dementia with Lewy bodies (DLB).
CervoMed's Neflamapimod Shows Promise in Dementia with Lewy Bodies
CervoMed will present new data on neflamapimod's potential in treating dementia with Lewy bodies (DLB) at the CTAD conference.